Sulphated Polysaccharide from Prasinococcus capsulatus for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Microalgae-derived polysaccharides have not been significantly utilized for therapeutic or cosmetic purposes, and there is a lack of characterization of products from microalgae, limiting their application in treating immune system disorders and inflammatory conditions.
Innovation Solution
A sulphated heteropolymer polysaccharide from Prasinococcus capsulatus or related strains, with a molecular weight greater than 670 kDa, comprising glucose, galactose, arabinose, and uronic acid units, is developed for use in treating immune system disorders, including inflammatory conditions, and its derivatives are used in both therapeutic and cosmetic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If microalgae polysaccharides are utilized for therapeutic purposes, then treatment efficacy for immune system disorders is improved, but the lack of characterization limits their application
Solution Approach 1:
The patent applies parameter changes by systematically analyzing and characterizing the polysaccharide through multiple parameters including molecular weight (>670 kDa), sulphate content (25-35% w/w), monosaccharide composition (glucose, galactose, arabinose, uronic acid), and viscosity. This comprehensive parameter characterization transforms the previously undefined microalgae polysaccharide into a well-defined therapeutic agent with reliable and reproducible treatment efficacy for immune system disorders.
2Quantity of substance
If macroalgae are exploited to provide established products, then product availability is improved, but microalgae have not yet been significantly used
Solution Approach 1:
The patent demonstrates universality by showing that the characterized polysaccharide from microalgae Prasinococcus capsulatus can be applied across multiple therapeutic areas including inflammatory disorders, autoimmune conditions, and allergic reactions. The polysaccharide's defined composition and immunomodulatory properties enable it to serve as a versatile therapeutic agent, expanding the application scope beyond what was previously achieved with macroalgae products.
3Reliability
If polysaccharide composition is well-defined, then therapeutic reliability is improved, but production complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing the polysaccharide composition, molecular weight, and sulphate content during the production process. By establishing these parameters early in the production workflow and setting specific targets (e.g., molecular weight >670 kDa, sulphate content 25-35% w/w), the process ensures therapeutic reliability is built into the product from the outset, rather than requiring complex post-production adjustments or quality control interventions.
Data Source
AI summary
There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives in the treatment of disorders of the immune system.